Ein kostenloses Konto anlegen
Registrieren Sie sich bei Calaméo, um Dokumente weltweit zu veröffentlichen und weiterzugeben!
Außerdem: Bewerten und kommentieren Sie Ihre bevorzugten Publikationen. Laden Sie Dokumente herunter und tauschen Sie sich mit Ihren Freunden über Ihre Lektüre aus.
Anticonvulsants Market to 2016
2 Seiten
Veröffentlicht von
rgunnam
Anticonvulsants Market to 2016 - Cost Advantage and Dosage Convenience Provided by
Generic Anticonvulsants Will Limit Commercial Opportunities for Novel Therapies
Patent Expiries of the Leading Anticonvulsants Followed by Generics...
[Mehr]
Anticonvulsants Market to 2016 - Cost Advantage and Dosage Convenience Provided by
Generic Anticonvulsants Will Limit Commercial Opportunities for Novel Therapies
Patent Expiries of the Leading Anticonvulsants Followed by Generics Erosions Will
Decline the Anticonvulsants Market by a CAGR of 0.
1% in The Future
Various anticonvulsants, both branded and off-label are being used for the treatment of
many indications such as epilepsy, fibromyalgia, migraine, neuropathic pain, bipolar
disorder and anxiety.
The patents of leading anticonvulsants such as Topamax
(topiramate), Trileptal (oxcarbazepine), Depakote (divalproex sodium), Keppra
(levetiracetam), Lamictal (lamotrigine) and Tegretol (carbamazepine) expired in 20072008.
The wide applicability of the anticonvulsants for management of the various
indications has caused the emergence of generics for these anticonvulsants in the market.
This generic erosion will cause decline in the anticonvulsant market in the future.
For Sample Page
[Weniger]
Schlagworte
anticonvulsant,
anticonvulsants,
convenience,
dosage,
epilepsy,
fibromyalgia,
generic,
indications,
lyrica,
market,
neuropathic,
opportunities,
pain,
provided,
report,
research,
treatment
